摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

7-amino(1,2,3)triazolo(1,5-a)pyridine | 127682-62-6

中文名称
——
中文别名
——
英文名称
7-amino(1,2,3)triazolo(1,5-a)pyridine
英文别名
7-amino<1,2,3>triazolo<1,5-a>pyridine;7-aminotriazolopyridine;[1,2,3]triazolo[1,5-a]pyridin-7-amine;triazolo[1,5-a]pyridin-7-amine
7-amino(1,2,3)triazolo(1,5-a)pyridine化学式
CAS
127682-62-6
化学式
C6H6N4
mdl
MFCD01318224
分子量
134.14
InChiKey
LZISVZBSKHHYQG-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.2
  • 重原子数:
    10
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    56.2
  • 氢给体数:
    1
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    7-amino(1,2,3)triazolo(1,5-a)pyridine硫酸 作用下, 反应 2.0h, 以35%的产率得到2-氨基-6-吡啶甲醇
    参考文献:
    名称:
    三唑并吡啶。14. 7-氨基[1,2,3]三唑并[1,5-a]吡啶的取代反应。
    摘要:
    7-氨基三唑并吡啶1或2与硫酸反应,得到羟烷基吡啶3和4。溴化得到溴化吡啶5或三唑并吡啶6。来自胺1或2的阴离子是环境性的,在N上酰化但在N或C6上烷基化;在后一种情况下triazolylalkenylcyanides 16 - 20或6,6-二烷基化衍生物19获得。X射线衍射研究已证实结构19。
    DOI:
    10.1016/s0040-4020(01)86272-4
  • 作为产物:
    描述:
    7-lithiotriazolopyridine 在 (E)-(2-azidovinyl)benzene 作用下, 以4.2%的产率得到7-amino(1,2,3)triazolo(1,5-a)pyridine
    参考文献:
    名称:
    Triazolopyridines. Part 9. The synthesis of7-amino(1,2,3)triazolo(1,5-a)pyridines
    摘要:
    DOI:
    10.1016/s0040-4020(01)89172-9
点击查看最新优质反应信息

文献信息

  • Derivatives of n-(1h-indazolyl)-and n-(1h-indolyl)-urea as well as related compounds as modulators of the vanilloid-1 receptor (vr1) for treatment of pain
    申请人:Fletcher Robert Stephen
    公开号:US20070078156A1
    公开(公告)日:2007-04-05
    Compounds of formula (I): wherein A, B and D are each C, N, O or S; E is C or N; the dotted circle within the five-membered ring indicates that the ring may be unsaturated or partially saturated; R 1 is halogen, hydroxy, C 1-6 alkyl, haloC 1-6 alkyl, hydroxyC 1-6 alkyl, C 1-6 alkoxy, halo C 1-6 alkoxy, hydroxyC 1-6 alkoxy, C 3-7 cycloalkyl, C 3-5 cycloalkylC 1-4 alkyl, NR 7 R 8 , C 1-6 alkyl substituted with NR 7 R 8 , C, 1-6 alkoxy substituted with NR 7 R 8 , oxo, cyano, SO 2 NR 7 R 8 , CONR 7 R 8 , NHCOR 9 or NHSO 2 R 9 ; R 2 is halogen, hydroxy, C 1-6 alkyl, halo C 1-6 alkyl, hydroxyC 1-6 alkyl, C 1-6 alkoxy, halo C 1-6 alkoxy, hydroxyC 1-6 alkoxy, C 3-7 cycloalkyl, C 3-5 cycloalkylC 1-4 alkyl, NR 7 R 8 , C 1-6 alkyl substituted with NR 7 R 8 , C 1-6 , alkoxy substituted with NR 7 R 8 , cyano, SON 2 R 7 R 8 , CONR 7 R 8 , NHCOR 9 , or NHSO 2 R 9 ; R 3 and R 4 are each independently hydrogen, C 1-6 , alkyl, phenyl or halophenyl; R 5 and R 6 are, at each occurrence, independently hydrogen, C 1-6 alkyl, phenyl, halophenyl or carboxy; X is an oxygen or sulfur atom; Y is an aryl, heteroaryl, carbocyclyl or fused-carbocyclyl group; n is either zero or an integer from 1 to 3; p is either zero or an integer from, 1 to 4; and q is either zero or an integer from 1 to 3; the other substituents are defined in claim 1; are useful as therapeutic compounds, particularly in the treatment of pain and other conditions ameliorated by the modulation of the function of the vanilloid-1 receptor (VR1).
    式(I)的化合物:其中A、B和D分别为C、N、O或S;E为C或N;五元环内的点圈表示该环可能不饱和或部分饱和;R1为卤素、羟基、C1-6烷基、卤代C1-6烷基、羟基C1-6烷基、C1-6烷氧基、卤代C1-6烷氧基、羟基C1-6烷氧基、C3-7环烷基、C3-5环烷基C1-4烷基、NR7R8、C1-6烷基取代的NR7R8、C1-6烷氧基取代的NR7R8、氧代、氰基、SO2NR7R8、CONR7R8、NHCOR9或NHSO2R9;R2为卤素、羟基、C1-6烷基、卤代C1-6烷基、羟基C1-6烷基、C1-6烷氧基、卤代C1-6烷氧基、羟基C1-6烷氧基、C3-7环烷基、C3-5环烷基C1-4烷基、NR7R8、C1-6烷基取代的NR7R8、C1-6烷氧基取代的NR7R8、氰基、SON2R7R8、CONR7R8、NHCOR9或NHSO2R9;R3和R4分别独立地为氢、C1-6烷基、苯基或卤代苯基;R5和R6在每次出现时独立地为氢、C1-6烷基、苯基、卤代苯基或羧基;X为氧或硫原子;Y为芳基、杂芳基、碳环基或融合碳环基基团;n为零或1至3的整数;p为零或1至4的整数;q为零或1至3的整数;其他取代基在权利要求中定义;在治疗疼痛和其他通过调节vanilloid-1受体(VR1)功能改善的疾病中特别有用的治疗化合物。
  • [EN] DERIVATIVES OF N-(1H-INDAZOLYL)- AND N-(1H-INDOLYL)-UREA AS WELL AS RELATED COMPOUNDS AS MODULATORS OF THE VANILLOID-1 RECEPTOR (VR1) FOR THE TREATMENT OF PAIN<br/>[FR] UREES HETEROAROMATIQUES MODULANT LA FONCTION DU RECEPTEUR VANILLOIODE-1 (VR1)
    申请人:MERCK SHARP & DOHME
    公开号:WO2005028445A3
    公开(公告)日:2005-06-02
  • Abarca, Belen; Asensio, Amparo; Ballesteros, Rafael, Journal of Chemical Research, Miniprint, 1990, # 1, p. 347 - 354
    作者:Abarca, Belen、Asensio, Amparo、Ballesteros, Rafael、Bosch, Jordi、Jones, Gurnos、et al.
    DOI:——
    日期:——
  • DERIVATIVES OF N-(1H-INDAZOLYL)- AND N-(1H-INDOLYL)-UREA AS WELL AS RELATED COMPOUNDS AS MODULATORS OF THE VANILLOID-1 RECEPTOR (VR1) FOR THE TREATMENT OF PAIN
    申请人:MERCK SHARP & DOHME LTD.
    公开号:EP1675587A2
    公开(公告)日:2006-07-05
  • [EN] HETEROAROMATIC UREAS WHICH MODULATE THE FUNCTION OF THE VANILLOID-1 RECEPTOR (VR1)<br/>[FR] UREES HETEROAROMATIQUES MODULANT LA FONCTION DU RECEPTEUR VANILLOIODE-1 (VR1)
    申请人:MERCK SHARP & DOHME
    公开号:WO2005028445A2
    公开(公告)日:2005-03-31
    Compounds of formula (I): wherein A, B and D are each C, N, O or S; E is C or N; the dotted circle within the five-membered ring indicates that the ring may be unsaturated or partially saturated;. R 1 is halogen, hydroxy, C 1-6 álkyl, haloC 1-6 alkyl, hydroxyC 1-6 alkyl, C 1-6 alkoxy, halo C 1-6 alkoxy, hydroxyC 1-6 alkoxy, C 3-7 cycloalkyl, C 3-5 cycloalkylC 1-4 alkyl, NR7R8, C 1-6 alkyl substituted with NR7R8, C, 1-6 alkoxy substituted with NR7R8, oxo, cyano, SO2NR7R8, CONR7R8, NHCOR9 or NHSO2R 9 ; R2 is halogen, hydroxy, C 1-6 alkyl, halo C 1-6 alkyl, hydroxyC 1-6 alkyl, C 1-6 alkoxy, halo C 1-6 alkoxy, hydroxyC 1-6 alkoxy, C 3-7 cycloalkyl, C 3-5 cycloalkylC 1-4 alkyl, NR7R8, C 1-6 alkyl substituted with NR7R8, C 1-6 , alkoxy substituted with NR7R8, cyano, SON2R7R8, CONR7R8, NHCOR9 , or NHSO2R9; R3 and R 4 are each independently hydrogen, C 1-6 ,alkyl, phenyl or halophenyl; R5 and R 6 are, at each occurrence, independently hydrogen, C 1-6 alkyl, phenyl, halophenyl or carboxy; X is an oxygen or sulfur atom; Y is an aryl, heteroaryl, carbocyclyl or fused-carbocyclyl group; n is either zero or an integer from 1 to 3; p is either zero or an integer from, 1 to 4; and q is either zero or an integer from 1 to 3; the other substituents are defined in claim 1; are useful as therapeutic compounds, particularly in the treatment of pain and other conditions ameliorated by the modulation of the function of the vanilloid-1 receptor (VR1).
查看更多

同类化合物

苯甲醇,2-甲基-a-[1-(甲基氨基)环戊基]- 溴-6-甲基[1,2,4]噻唑并[1,5-a]吡啶 乙基[1,2,4]三唑并[1,5-a]吡啶-2-羧酸酯 三(二甲基氨基)(3H-1,2,3-三唑[4,5-b]吡啶-3-基氧代)膦六氟磷酸盐 [1,2,4]噻唑并[4,3-a]吡啶-3-羧酸 [1,2,4]噻唑并[1,5-a]吡啶-8-胺 [1,2,4]噻唑并[1,5-a]吡啶-6-羧酸甲酯 [1,2,4]噻唑并[1,5-a]吡啶-6-羧酸 [1,2,4]噻唑并[1,5-a]吡啶-6-甲腈 [1,2,4]噻唑并[1,5-a]吡啶-6-甲胺 [1,2,4]噻唑并[1,5-a]吡啶-5-羧醛 [1,2,4]噻唑并[1,5-a]吡啶-5-羧酸甲酯 [1,2,4]噻唑并[1,5-a]吡啶-2-羧醛 [1,2,4]三氮唑[1,5-A]吡啶-6-甲醛 [1,2,4]三唑并[4,5-a]吡啶-3-磺酰胺 [1,2,4]三唑并[4,3-a]吡啶-5-羧酸 [1,2,4]三唑并[4,3-a]吡啶-5-硫醇 [1,2,4]三唑并[4,3-A]吡啶-8-胺 [1,2,4]三唑并[4,3-A]吡啶-7-羧酸 [1,2,4]三唑并[1,5-a]吡啶-7-羧酸 [1,2,4]三唑并[1,5-a]吡啶-6-胺 [1,2,4]三唑并[1,5-a]吡啶-5-羧酸 [1,2,4]三唑并[1,5-a]吡啶 [1,2,4]三唑并[1,5-A]吡啶-7-羧酸甲酯 [1,2,4]三唑并[1,5-A]吡啶-7-硼酸 [1,2,4]三唑[4,3-A]嘧啶-6-羧酸 [1,2,4]三唑[4,3-A]吡啶-3-硫醇 [1,2,4]三唑[1,5-a]吡啶-2-甲酸 [1,2,3]三唑并[1,5-a]吡啶-7-甲醛 [1,2,3]三唑并[1,5-a]吡啶-7-甲酰胺 [1,2,3]三唑并[1,5-a]吡啶-3-甲酰胺 [1,2,3]三唑并[1,5-a]吡啶-3-甲酰氯 N-羟基-7-氮杂苯并三氮唑 N-[5-[(1-甲基乙基)氨基]-7-(三氟甲基)[1,2,4]三唑并[1,5-a]吡啶-2-基]-3-吡啶甲酰胺 N,N-二乙基-7-硝基-1H-1,2,3-三唑并[4,5-c]吡啶-1-乙胺 GLPG-0634 中间体 ALK4/ALK5抑制剂 9-环戊基-7-乙基-3-(2-噻吩基)-6,9-二氢-5H-吡唑并[3,4-c][1,2,4]三唑并[4,3-A]吡啶 8-硝基[1,2,4]三唑并[4,3-a]吡啶 8-硝基[1,2,4]三唑并[1,5-a]吡啶 8-甲氧基-[1,2,4]噻唑并[1,5-a]吡啶-2-胺 8-甲氧基-5-碘-[1,2,4]噻唑并[1,5-a]吡啶-2-胺 8-甲基-[1,2,4]三唑并[1,5-A]吡啶 8-甲基-1,2,4噻唑并1,5-a吡啶-2-胺 8-溴2-甲基-[1,2,4]噻唑并[1,5-a]吡啶 8-溴-[1,2,4]噻唑并[1,5-a]吡啶-2-胺 8-溴-[1,2,4]三氮唑并[4,3-A]吡啶 8-溴-[1,2,4]三唑并[1,5-A]吡啶 8-溴-[1,2,4]三唑[4,3-a]吡啶-6-羧酸 8-溴-6-氯-2-甲基-[1,2,4]噻唑并[1,5-a]吡啶